| 70 | N | N | N | Moricizine hydrochloride
 | KCNK5: potassium channel, subfamily K, member 5 | 0.43243 | Dyclonine hydrochloride
 | 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 74 | N | N | N | Amiloride hydrochloride
 | SCN4B | 0.26923 | Riluzole
 | 0.025789 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
| 83 | N | N | N | Amiloride hydrochloride
| SCN7A: sodium channel, voltage-gated, type VII, alpha | 0.26923 | Riluzole
| 0.087772 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 92 | N | N | N | Amiloride hydrochloride
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.26923 | Riluzole
| 0.024163 | ACCN3: amiloride-sensitive cation channel 3 |
| 95 | N | N | N | Amiloride hydrochloride
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.26923 | Riluzole
| 0.024794 | ACCN1: amiloride-sensitive cation channel 1, neuronal |
| 110 | N | N | N | Phenytoin
 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.37500 | Dizocilpine maleate
 | 0.022827 | SCN4B |
| 111 | N | N | N | Verapamil
 | GRIA3: glutamate receptor, ionotrophic, AMPA 3 | 0.20000 | Riluzole
| 0.026689 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 114 | N | N | N | Verapamil
| GRIA4: glutamate receptor, ionotrophic, AMPA 4 | 0.20000 | Riluzole
| 0.026577 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 117 | N | N | N | Flecainide acetate
 | KCNK5: potassium channel, subfamily K, member 5 | 0.38461 | Dyclonine hydrochloride
| 0.030801 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 150 | N | N | N | Lamotrigine
 | KCNK5: potassium channel, subfamily K, member 5 | 0.30435 | Diazoxide
 | 0.013225 | SCN9A: sodium channel, voltage-gated, type IX, alpha subunit |
| 164 | N | N | N | Diazoxide
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.38095 | Riluzole
| 0.19653 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 176 | N | N | N | Doxorubicin hydrochloride
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.23729 | Glyburide
 | 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
| 189 | N | N | N | Kainic acid hydrate
 | GRID2: glutamate receptor, ionotropic, delta 2 | 0 | Riluzole
| 0.20292 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 194 | N | N | N | Verapamil
| GRIA2: glutamate receptor, ionotropic, AMPA 2 | 0.20000 | Riluzole
| 0.027448 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 206 | N | N | N | Doxorubicin hydrochloride
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.24624 | Ketoconazole
 | 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
| 208 | N | N | N | Streptomycin sulfate
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.066667 | Glyburide
| 0.0043818 | RYR2: ryanodine receptor 2 (cardiac) |
| 210 | N | N | N | Verapamil
| MCOLN1: mucolipin 1 | 0.085106 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 217 | N | N | N | Haloperidol
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42492 | Thioridazine hydrochloride
 | 0.015023 | GRIN2C: glutamate receptor, ionotropic, N-methyl D-aspartate 2C |
| 219 | N | N | N | Halothane
 | RYR2: ryanodine receptor 2 (cardiac) | 0.078947 | Pimozide
 | 0.021708 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
| 222 | N | N | N | Verapamil
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.085106 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 224 | N | N | N | Halothane
| RYR3 | 0.078947 | Pimozide
| 0.021825 | ITPR3: inositol 1,4,5-trisphosphate receptor, type 3 |
| 228 | N | N | N | Riluzole
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.45833 | Hydroflumethiazide
 | 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 229 | N | N | N | Ethosuximide
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.47059 | Butabarbital
 | 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 256 | N | N | N | Verapamil
| CLCN2: chloride channel 2 | 0.11111 | Lubiprostone
 | 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 262 | N | N | N | Verapamil
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.29412 | Glyburide
| 0.15287 | ABCC9: ATP-binding cassette, sub-family C (CFTR/MRP), member 9 |
| 281 | N | N | N | Streptomycin sulfate
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.075630 | Verapamil
| 0.0071212 | RYR2: ryanodine receptor 2 (cardiac) |
| 288 | N | N | N | Propofol
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.22727 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
| 301 | N | N | N | Halothane
| RYR1: ryanodine receptor 1 (skeletal) | 0.078947 | Pimozide
| 0.021654 | ITPR1: inositol 1,4,5-trisphosphate receptor, type 1 |
| 310 | N | N | N | Ketamine hydrochloride
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.38710 | Thioridazine hydrochloride
| 0.024001 | GABRA6: gamma-aminobutyric acid (GABA) A receptor, alpha 6 |
| 329 | N | N | N | Propofol
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.26471 | Diltiazem hydrochloride
 | 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 336 | N | N | N | Magnesium sulfate
 | CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.027027 | Nifedipine
 | 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 343 | N | N | N | Paramethadione
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30435 | Methohexital
 | 0.011438 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 354 | N | N | N | Verapamil
| CHRND: cholinergic receptor, nicotinic, delta | 0.29268 | Metoclopramide
 | 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 360 | N | N | N | Verapamil
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.20000 | Riluzole
| 0.020345 | KCNE1L: KCNE1-like |
| 363 | N | N | N | Dofetilide
 | KCNK6: potassium channel, subfamily K, member 6 | 0.41270 | Ibutilide fumarate
 | 0.19314 | KCNK2: potassium channel, subfamily K, member 2 |
| 369 | N | N | N | Verapamil
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.17500 | Caffeine
 | 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
| 370 | N | N | N | Diazoxide
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.27027 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 371 | N | N | N | Flecainide acetate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.27027 | Riluzole
| 0.015652 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 374 | N | N | N | Verapamil
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.29268 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
| 375 | N | N | N | Indapamide
 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.42857 | Benzthiazide
 | 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 376 | N | N | N | Amlexanox
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.38235 | Caffeine and sodium benzoate
 | 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 381 | N | N | N | Tolbutamide
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.41667 | Glyburide
| 0.14579 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 386 | N | N | N | Levetiracetam
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.26087 | Ketamine hydrochloride
| 0.0099594 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 391 | N | N | N | Diazoxide
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.022598 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 392 | N | N | N | Verapamil
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
 | 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
| 394 | N | N | N | Ibutilide fumarate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.29167 | Verapamil
| 0.19447 | CACNA2D1: calcium channel, voltage-dependent, alpha 2/delta subunit 1 |
| 397 | N | N | N | Ethosuximide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.15790 | Gabapentin
 | 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 399 | N | N | N | Amlexanox
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.37500 | Repaglinide
 | 0.013742 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 401 | N | N | N | Verapamil
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
| 410 | N | N | N | Encainide hydrochloride
 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.47059 | Bupivacaine hydrochloride
 | 0.016875 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
| 417 | N | N | N | Verapamil
| GLRA3 | 0.14583 | Tropisetron hydrochloride
 | 0.029733 | KCNE1L: KCNE1-like |
| 421 | N | N | N | Penfluridol
 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.48936 | Astemizole
 | 0.013728 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 432 | N | N | N | Lubiprostone
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.25926 | Penicillin G procaine
 | 0.013899 | CLCN2: chloride channel 2 |
| 433 | N | N | N | Verapamil
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.12245 | Cocaine
 | 0.033720 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 440 | N | N | N | Diazoxide
| MCOLN1: mucolipin 1 | 0.18518 | Amiloride hydrochloride
| 0.032255 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 445 | N | N | N | Diazoxide
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.18518 | Amiloride hydrochloride
| 0.027859 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 456 | N | N | N | Dopamine hydrochloride
 | GLRA3 | 0.21429 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 462 | N | N | N | Verapamil
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.17500 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 466 | N | N | N | Ondansetron hydrochloride hydrate
 | GLRA3 | 0.34286 | Tropisetron hydrochloride
| 0.095753 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 468 | N | N | N | Trifluoperazine maleate
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.45833 | Thioridazine hydrochloride
| 0.030674 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 470 | N | N | N | Benzocaine
 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.31034 | Nitrendipine
 | 0.12677 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 474 | N | N | N | Benzocaine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.31034 | Nitrendipine
| 0.12915 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 479 | N | N | N | Trimethadione
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.28571 | Hexobarbital
 | 0.0087226 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 486 | N | N | N | Dantrolene
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.41935 | Clobazam
 | 0.0064074 | RYR1: ryanodine receptor 1 (skeletal) |
| 487 | N | N | N | Cetiedil citrate
 | CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.20690 | Glyburide
| 0.010929 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 490 | N | N | N | Disopyramide
 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.34884 | Verapamil
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 492 | N | N | N | Ketoconazole
| CFTR: cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) (EC:3.6.3.49) | 0.40816 | Glyburide
| 0.011075 | KCNA10: potassium voltage-gated channel, shaker-related subfamily, member 10 |
| 495 | N | N | N | Diazoxide
| SCN4B | 0.40000 | Zonisamide
 | 0.044678 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 501 | N | N | N | Cetiedil citrate
| CHRNA2 | 0.33962 | Nicotine bitartrate
 | 0.019239 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 503 | N | N | N | Riluzole
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.23077 | Ketamine hydrochloride
| 0.15710 | GRIK1: glutamate receptor, ionotropic, kainate 1 |
| 506 | N | N | N | Verapamil
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.17500 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
| 516 | N | N | N | Disopyramide
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.34884 | Verapamil
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 517 | N | N | N | Mefloquine hydrochloride
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.31250 | Riluzole
| 0.011082 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 518 | N | N | N | Glyburide
| KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 | 0.40816 | Ketoconazole
| 0.017942 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 520 | N | N | N | Diazepam
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.30769 | Diazoxide
| 0.018959 | GLRA1: glycine receptor, alpha 1 |
| 524 | Y | Y | Y | Repaglinide
| ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.43478 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 525 | N | N | N | Ibutilide fumarate
| KCNK16: potassium channel, subfamily K, member 16 | 0.29167 | Verapamil
| 0.24996 | KCNK6: potassium channel, subfamily K, member 6 |
| 527 | N | N | N | Zonisamide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.40000 | Diazoxide
| 0.016547 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 528 | N | N | N | Verapamil
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.17500 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 533 | N | N | N | Amlodipine maleate
 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nisoldipine
 | 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 535 | N | N | N | Halazepam
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.39286 | Riluzole
| 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 537 | N | N | N | Amlodipine besylate
 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 | 0.48837 | Nitrendipine
| 0.018083 | CACNA1F: calcium channel, voltage-dependent, L type, alpha 1F subunit |
| 539 | N | N | N | Verapamil
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.17500 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 544 | N | N | N | Diazoxide
| CHRND: cholinergic receptor, nicotinic, delta | 0.25926 | Metoclopramide
| 0.029958 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 546 | N | N | N | Dequalinium chloride
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.34783 | Thioridazine hydrochloride
| 0.032967 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 547 | N | N | N | Verapamil
| GABRR2 | 0.30233 | Zaleplon
 | 0.030883 | KCNE1L: KCNE1-like |
| 555 | N | N | N | Mefloquine hydrochloride
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.47500 | Flecainide acetate
| 0.081115 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 560 | N | N | N | Pramoxine hydrochloride
 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.38461 | Flecainide acetate
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 561 | N | Y | Y | Nateglinide
 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 | 0.36585 | Glyburide
| 0.013742 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 563 | N | N | N | Verapamil
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.17500 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 564 | N | N | N | Exemestane
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.34483 | Hexobarbital
| 0.090264 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 565 | N | N | N | Riluzole
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38095 | Diazoxide
| 0.025836 | SCN4A: sodium channel, voltage-gated, type IV, alpha subunit |
| 570 | N | Y | N | Magnesium sulfate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.027027 | Nifedipine
| 0.015801 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 577 | N | N | N | Cyproheptadine hydrochloride
 | CHRNA2 | 0.39317 | Tubocurarine chloride
 | 0.018097 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 581 | N | N | N | Zonisamide
| CACNA1E: calcium channel, voltage-dependent, R type, alpha 1E subunit | 0.22222 | Phenytoin
| 0.12631 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 582 | N | N | N | Dofetilide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41026 | Benzthiazide
| 0.022874 | KCNK2: potassium channel, subfamily K, member 2 |
| 583 | N | N | N | Ibutilide fumarate
| KCNK2: potassium channel, subfamily K, member 2 | 0.41270 | Dofetilide
| 0.20401 | KCNK1: potassium channel, subfamily K, member 1 |
| 590 | N | N | N | Diazoxide
| CHRNB1: cholinergic receptor, nicotinic, beta 1 (muscle) | 0.25926 | Metoclopramide
| 0.035142 | KCNK4: potassium channel, subfamily K, member 4 |
| 596 | N | N | N | Magnesium sulfate
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.10345 | Glyclopyramide
 | 0.025831 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 600 | N | N | N | Letrozole
 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.34884 | Ketoconazole
| 0.017956 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 604 | N | N | N | Granisetron
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.48387 | Nateglinide
| 0.017658 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 606 | N | N | N | Diazoxide
| SCN3B: sodium channel, voltage-gated, type III, beta | 0.40000 | Zonisamide
| 0.046014 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 610 | N | N | N | Dequalinium chloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40000 | Halofantrine hydrochloride
 | 0.017196 | KCNN1: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1 |
| 620 | N | N | N | Diazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38889 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 626 | N | N | N | Diazoxide
| SLC6A1: solute carrier family 6 (neurotransmitter transporter, GABA), member 1 | 0.16129 | Cocaine
| 0.026833 | KCND2: potassium voltage-gated channel, Shal-related subfamily, member 2 |
| 633 | N | N | N | Benzocaine
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.31034 | Nitrendipine
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 637 | N | N | N | Verapamil
| P2RX4: purinergic receptor P2X, ligand-gated ion channel, 4 | 0.17500 | Caffeine
| 0.033352 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 641 | N | N | N | Diazoxide
| SCN1B: sodium channel, voltage-gated, type I, beta | 0.40000 | Zonisamide
| 0.045507 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 647 | N | N | N | Halofantrine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
 | 0.012494 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 |
| 649 | N | N | N | Phentermine
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.38889 | Mexiletine hydrochloride
 | 0.010278 | SLC6A3: solute carrier family 6 (neurotransmitter transporter, dopamine), member 3 |
| 650 | N | N | N | Dyclonine hydrochloride
| KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 | 0.45161 | Bupivacaine hydrochloride
| 0.026637 | KCNK5: potassium channel, subfamily K, member 5 |
| 651 | N | N | N | Diazoxide
| P2RX2: purinergic receptor P2X, ligand-gated ion channel, 2 | 0.21739 | Caffeine
| 0.042682 | KCNK4: potassium channel, subfamily K, member 4 |
| 656 | N | N | N | Nateglinide
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44828 | Mepivacaine hydrochloride
 | 0.0099976 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 664 | N | N | N | Riluzole
| CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.26923 | Amiloride hydrochloride
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 667 | N | N | N | Bepridil hydrochloride
 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.45714 | Trimipramine
 | 0.014048 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 669 | N | N | N | Disopyramide
| CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit | 0.34884 | Verapamil
| 0.13951 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 682 | N | N | N | Amlexanox
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38710 | Furosemide
 | 0.010906 | ABCC8: ATP-binding cassette, sub-family C (CFTR/MRP), member 8 |
| 683 | N | N | N | Benzocaine
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.45000 | Felbamate
 | 0.022827 | SCN4B |
| 685 | N | N | N | Phenacemide
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.38461 | Nateglinide
| 0.011295 | SCN1A: sodium channel, voltage-gated, type I, alpha subunit |
| 691 | N | N | N | Mefloquine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.31707 | Bendroflumethiazide
 | 0.022575 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 695 | N | N | N | Diazoxide
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.40000 | Zonisamide
| 0.030864 | KCNV1: potassium channel, subfamily V, member 1 |
| 698 | N | Y | N | Magnesium sulfate
| CACNB1: calcium channel, voltage-dependent, beta 1 subunit | 0.042857 | Ibutilide fumarate
| 0.016265 | CACNG1: calcium channel, voltage-dependent, gamma subunit 1 |
| 703 | N | N | N | Codeine sulfate
 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.39744 | Quinine sulfate
 | 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 704 | N | N | N | Verapamil
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.36585 | Profenamine hydrochloride
 | 0.023718 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 708 | N | N | N | Mefloquine hydrochloride
| GLRA1: glycine receptor, alpha 1 | 0.32432 | Tropisetron hydrochloride
| 0.015107 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 709 | N | N | N | Felbamate
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.18518 | Riluzole
| 0.092521 | GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A |
| 713 | N | N | N | Azimilide dihydrochloride
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 716 | N | N | N | Ethchlorvynol
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.21429 | Methoxyflurane
 | 0.011445 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 722 | N | N | N | Verapamil
| HTR3D: 5-hydroxytryptamine (serotonin) receptor 3 family member D | 0.23404 | Ondansetron hydrochloride hydrate
| 0.042488 | KCNMB1: potassium large conductance calcium-activated channel, subfamily M, beta member 1 |
| 726 | N | Y | N | Amlodipine besylate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nitrendipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 733 | N | N | N | Diazoxide
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0 | Proline
| 0.033290 | KCNK17: potassium channel, subfamily K, member 17 |
| 738 | N | N | N | Fluphenazine maleate
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48837 | Thioridazine hydrochloride
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 740 | N | N | N | Ethosuximide
| CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) | 0.44444 | Pentobarbital
 | 0.0094499 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 745 | N | N | N | Dopamine hydrochloride
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35294 | Chlorzoxazone
 | 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 748 | N | N | N | Mefloquine hydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.24390 | Indapamide
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 751 | N | N | N | Diazoxide
| GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 | 0.29167 | Ketamine hydrochloride
| 0.14656 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 752 | N | N | N | Maprotiline
 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.45714 | Moricizine
 | 0.0094747 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 |
| 753 | N | N | N | Nicotine bitartrate
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.24490 | Quinine hydrochloride hydrate
 | 0.18777 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 758 | N | N | N | Sumatriptan
 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.36000 | Diazoxide
| 0.015696 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 761 | N | N | N | Dofetilide
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.41270 | Ibutilide fumarate
| 0.011007 | KCNH5: potassium voltage-gated channel, subfamily H (eag-related), member 5 |
| 764 | N | Y | N | Quinidine sulfate
 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.32836 | Astemizole
| 0.22326 | KCNH1: potassium voltage-gated channel, subfamily H (eag-related), member 1 |
| 765 | N | Y | N | Amlodipine maleate
| CACNB2: calcium channel, voltage-dependent, beta 2 subunit | 0.48837 | Nisoldipine
| 0.017211 | CACNA1A: calcium channel, voltage-dependent, P/Q type, alpha 1A subunit |
| 768 | N | N | N | Mibefradil dihydrochloride
 | PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.44898 | Verapamil
| 0.0049566 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 770 | N | N | N | Diazoxide
| P2RX7: purinergic receptor P2X, ligand-gated ion channel, 7 | 0.21739 | Caffeine
| 0.027427 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 772 | N | N | N | Nortriptyline hydrochloride
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.48387 | Dizocilpine maleate
| 0.024221 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 775 | N | N | N | Mibefradil dihydrochloride
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.44898 | Verapamil
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 776 | N | N | N | Diazoxide
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0 | Proline
| 0.031499 | KCNK16: potassium channel, subfamily K, member 16 |
| 777 | N | N | N | Propafenone hydrochloride
 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34091 | Verapamil
| 0.21997 | KCNA5: potassium voltage-gated channel, shaker-related subfamily, member 5 |
| 778 | N | N | N | Amlodipine besylate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nitrendipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 779 | N | N | N | Diazoxide
| GLRA3 | 0.24138 | Tropisetron hydrochloride
| 0.029733 | KCNE1L: KCNE1-like |
| 780 | N | N | N | Phencyclidine hydrochloride
 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.31250 | Bupivacaine hydrochloride
| 0.18777 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 |
| 781 | N | N | N | Dopamine hydrochloride
| GLRA2: glycine receptor, alpha 2 | 0.26087 | Felbamate
| 0.10113 | HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A |
| 788 | N | N | N | Lamotrigine
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.35000 | Chlorzoxazone
| 0.011633 | SCN3A: sodium channel, voltage-gated, type III, alpha subunit |
| 790 | N | N | N | Diazoxide
| SCN11A: sodium channel, voltage-gated, type XI, alpha subunit | 0.16129 | Cocaine
| 0.027170 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
| 791 | N | N | N | Penfluridol
| KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.48333 | Trifluoperazine hydrochloride
 | 0.011237 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 794 | N | N | N | Paroxetine
 | KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.43590 | Cisapride
 | 0.013109 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 798 | N | N | N | Zaleplon
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.37143 | Disopyramide
| 0.013396 | GABRE |
| 802 | N | N | N | Physostigmine sulfate
 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36986 | Quinine sulfate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 807 | N | N | N | Diazoxide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.38095 | Riluzole
| 0.092521 | GRIA1: glutamate receptor, ionotropic, AMPA 1 |
| 808 | N | N | N | Diazoxide
| ACCN2: amiloride-sensitive cation channel 2, neuronal | 0.18518 | Amiloride hydrochloride
| 0.026659 | KCNE1L: KCNE1-like |
| 815 | N | N | N | Diazoxide
| ACCN1: amiloride-sensitive cation channel 1, neuronal | 0.18518 | Amiloride hydrochloride
| 0.027845 | KCNE4: potassium voltage-gated channel, Isk-related family, member 4 |
| 816 | N | N | Y | Bepridil hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45454 | Terfenadine
 | 0.017204 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 817 | N | N | N | Dibucaine
 | KCNK5: potassium channel, subfamily K, member 5 | 0.44828 | Lidocaine
 | 0.011241 | SCN10A: sodium channel, voltage-gated, type X, alpha subunit |
| 820 | N | N | N | Sertraline
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.48276 | Midazolam
 | 0.014964 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 822 | N | N | N | Mefloquine hydrochloride
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.30769 | Halazepam
| 0.015344 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 826 | N | N | N | Codeine
 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.35294 | Bupivacaine hydrochloride
| 0.020018 | CHRNA10 |
| 827 | N | N | N | Diltiazem hydrochloride
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36956 | Verapamil
| 0.22001 | KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 |
| 830 | N | N | N | Penicillin G procaine
| CACNA1C: calcium channel, voltage-dependent, L type, alpha 1C subunit | 0.47676 | Diltiazem malate
 | 0.011266 | GABRA5: gamma-aminobutyric acid (GABA) A receptor, alpha 5 |
| 834 | N | N | N | Diazoxide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40000 | Zonisamide
| 0.025826 | KCNS2: potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2 |
| 838 | N | N | N | Ibutilide fumarate
| KCNK10: potassium channel, subfamily K, member 10 | 0.29167 | Verapamil
| 0.18687 | KCNK1: potassium channel, subfamily K, member 1 |
| 839 | N | N | N | Zonisamide
| PKD1: polycystic kidney disease 1 (autosomal dominant) | 0.22222 | Phenytoin
| 0.012238 | SCN1B: sodium channel, voltage-gated, type I, beta |
| 842 | N | N | N | Dizocilpine maleate
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Nortriptyline hydrochloride
| 0.024221 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 843 | N | N | N | Amiodarone hydrochloride
 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.42105 | Fluoxetine
 | 0.021769 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 848 | N | N | N | Promethazine teoclate
 | RYR1: ryanodine receptor 1 (skeletal) | 0.40476 | Caffeine and sodium benzoate
| 0.0072515 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 849 | Y | N | N | Diazoxide
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.40000 | Zonisamide
| 0.025645 | KCNF1: potassium voltage-gated channel, subfamily F, member 1 |
| 850 | N | N | N | Dyclonine hydrochloride
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.43333 | Tolazamide
 | 0.021462 | KCNK5: potassium channel, subfamily K, member 5 |
| 851 | N | N | N | Kainic acid hydrate
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.28125 | Dizocilpine maleate
| 0.096106 | GRIK2: glutamate receptor, ionotropic, kainate 2 |
| 853 | N | N | N | Dizocilpine maleate
| GRIK2: glutamate receptor, ionotropic, kainate 2 | 0.28125 | Kainic acid hydrate
| 0.15526 | GRIN1: glutamate receptor, ionotropic, N-methyl D-aspartate 1 |
| 854 | N | N | N | Flurazepam
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.43750 | Chloroprocaine hydrochloride
 | 0.012903 | GABRG2: gamma-aminobutyric acid (GABA) A receptor, gamma 2 |
| 855 | N | N | N | Sumatriptan
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.40741 | Tolbutamide
| 0.021953 | HTR3E: 5-hydroxytryptamine (serotonin) receptor 3, family member E |
| 856 | N | N | N | Amlodipine maleate
| CACNA2D4: calcium channel, voltage-dependent, alpha 2/delta subunit 4 | 0.48837 | Nisoldipine
| 0.0092209 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 858 | N | N | Y | Flecainide acetate
| KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 | 0.34146 | Bupivacaine hydrochloride
| 0.24349 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 860 | N | N | N | Diltiazem hydrochloride
| KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 | 0.44444 | Fluoxetine
| 0.022791 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 861 | N | N | N | Carbamazepine
 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit | 0.37037 | Phenytoin
| 0.13120 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 862 | N | N | N | Diazoxide
| P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 | 0.21739 | Caffeine
| 0.045889 | KCNE1L: KCNE1-like |
| 865 | N | N | N | Kainic acid hydrate
| SLC6A14: solute carrier family 6 (amino acid transporter), member 14 | 0.33333 | Proline
| 0.015453 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 867 | N | N | N | Sertraline
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.42308 | Ketamine hydrochloride
| 0.010907 | SLC6A4: solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 |
| 871 | N | N | N | Indapamide
| KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.41026 | Glipizide
 | 0.027394 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 872 | N | N | N | Flecainide acetate
| GLRA1: glycine receptor, alpha 1 | 0.25714 | Sevoflurane
 | 0.019946 | KCNA2: potassium voltage-gated channel, shaker-related subfamily, member 2 |
| 875 | N | N | N | Glyclopyramide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.37838 | Cisapride
| 0.014705 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 877 | N | N | N | Mibefradil dihydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.44898 | Verapamil
| 0.13545 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 878 | N | N | N | Promethazine teoclate
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.38636 | Flurazepam
| 0.016138 | KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 |
| 881 | N | N | N | Hydroflumethiazide
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.45833 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 883 | N | N | N | Halazepam
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.48387 | Fluoxetine
| 0.016138 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 885 | N | N | N | Nifedipine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.38235 | Cocaine
| 0.13474 | CACNA1I: calcium channel, voltage-dependent, T type, alpha 1I subunit |
| 886 | N | N | N | Caffeine
| CLCN2: chloride channel 2 | 0.051282 | Lubiprostone
| 0.013935 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
| 887 | N | N | N | Trichlormethiazide
 | GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.40000 | Riluzole
| 0.0091408 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 889 | N | N | N | Trifluoperazine hydrochloride
| GRIA1: glutamate receptor, ionotropic, AMPA 1 | 0.32353 | Riluzole
| 0.018721 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 |
| 893 | N | N | N | Amiloride hydrochloride
| GRID2: glutamate receptor, ionotropic, delta 2 | 0.26923 | Riluzole
| 0.014175 | MCOLN1: mucolipin 1 |
| 896 | N | N | N | Felbamate
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45000 | Benzocaine
| 0.010173 | GLRA2: glycine receptor, alpha 2 |
| 898 | N | N | N | Caffeine
| MCOLN1: mucolipin 1 | 0.14286 | Amiloride hydrochloride
| 0.023510 | P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 |
| 900 | N | N | N | Kainic acid hydrate
| SLC6A7: solute carrier family 6 (neurotransmitter transporter, L-proline), member 7 | 0.33333 | Proline
| 0.012768 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 903 | N | N | N | Caffeine
| TRPC6: transient receptor potential cation channel, subfamily C, member 6 | 0.14286 | Amiloride hydrochloride
| 0.016201 | P2RX5: purinergic receptor P2X, ligand-gated ion channel, 5 |
| 904 | N | N | N | Diazoxide
| P2RX3: purinergic receptor P2X, ligand-gated ion channel, 3 | 0.21739 | Caffeine
| 0.030341 | KCNE2: potassium voltage-gated channel, Isk-related family, member 2 |
| 909 | N | N | N | Aminoglutethimide
 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.42105 | Ethosuximide
| 0.0080876 | CHRNB2: cholinergic receptor, nicotinic, beta 2 (neuronal) |
| 910 | N | N | N | Diazoxide
| P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 | 0.21739 | Caffeine
| 0.029220 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 912 | N | N | N | Halazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.38461 | Diltiazem hydrochloride
| 0.019068 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 914 | N | N | N | Trichlormethiazide
| GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.36667 | Furosemide
| 0.011447 | KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 |
| 915 | N | N | N | Riluzole
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.26923 | Amiloride hydrochloride
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 917 | N | N | N | Azimilide dihydrochloride
| KCNE1: potassium voltage-gated channel, Isk-related family, member 1 | 0.21818 | Verapamil
| 0.026945 | KCNQ1: potassium voltage-gated channel, KQT-like subfamily, member 1 |
| 918 | N | N | N | Flurazepam
| KCNA1: potassium voltage-gated channel, shaker-related subfamily, member 1 (episodic ataxia with myokymia) | 0.46154 | Diltiazem hydrochloride
| 0.019626 | GABRD: gamma-aminobutyric acid (GABA) A receptor, delta |
| 920 | N | N | N | Fluoxetine hydrochloride
 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 | 0.46875 | Halazepam
| 0.021675 | KCNJ6: potassium inwardly-rectifying channel, subfamily J, member 6 |
| 921 | N | N | N | Enoxacin hydrate
 | KCNN2: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 2 | 0.30682 | Trifluoperazine maleate
| 0.021832 | GABRA3: gamma-aminobutyric acid (GABA) A receptor, alpha 3 |
| 927 | N | N | N | Diazoxide
| P2RX1: purinergic receptor P2X, ligand-gated ion channel, 1 | 0.21739 | Caffeine
| 0.045455 | KCNE3: potassium voltage-gated channel, Isk-related family, member 3 |
| 928 | N | N | N | Amiodarone hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.42105 | Fluoxetine
| 0.027535 | KCNA7: potassium voltage-gated channel, shaker-related subfamily, member 7 |
| 929 | N | N | N | Verapamil
| GRIN2D: glutamate receptor, ionotropic, N-methyl D-aspartate 2D | 0.28261 | Haloperidol
| 0.029109 | KCNK4: potassium channel, subfamily K, member 4 |
| 932 | N | N | N | Ibutilide fumarate
| KCNK5: potassium channel, subfamily K, member 5 | 0.29167 | Verapamil
| 0.17161 | KCNK1: potassium channel, subfamily K, member 1 |
| 935 | N | N | N | Bepridil hydrochloride
| KCNN3: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 3 | 0.47059 | Desipramine hydrochloride
 | 0.035737 | KCNQ4: potassium voltage-gated channel, KQT-like subfamily, member 4 |
| 936 | N | N | N | Doxorubicin hydrochloride
| SCN5A: sodium channel, voltage-gated, type V, alpha subunit | 0.30508 | Quinidine gluconate
 | 0.0051579 | RYR1: ryanodine receptor 1 (skeletal) |
| 937 | N | N | N | Diazoxide
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.29167 | Ketamine hydrochloride
| 0.094588 | GRIA2: glutamate receptor, ionotropic, AMPA 2 |
| 938 | N | N | N | Phencyclidine hydrochloride
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.44444 | Dextromethorphan
 | 0.015803 | CHRNA10 |
| 939 | N | N | N | Propafenone hydrochloride
| KCNK16: potassium channel, subfamily K, member 16 | 0.34091 | Verapamil
| 0.24672 | KCNK5: potassium channel, subfamily K, member 5 |
| 940 | N | N | N | Indapamide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.43333 | Glyclopyramide
| 0.029070 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 945 | N | N | N | Codeine
| KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.38889 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 946 | N | N | N | Penicillin G procaine
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.40476 | Procaine hydrochloride
 | 0.011567 | GABRA2: gamma-aminobutyric acid (GABA) A receptor, alpha 2 |
| 947 | N | N | N | Pramoxine hydrochloride
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.42105 | Cisapride
| 0.019783 | KCNK5: potassium channel, subfamily K, member 5 |
| 953 | N | N | N | Cetiedil citrate
| SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.31707 | Methylphenidate
 | 0.022059 | KCNN4: potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4 |
| 954 | N | N | N | Quinine sulfate
| CHRNA2 | 0.39744 | Codeine sulfate
| 0.017256 | KCNA3: potassium voltage-gated channel, shaker-related subfamily, member 3 |
| 955 | Y | N | N | Glyburide
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.45652 | Astemizole
| 0.015300 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 956 | N | N | N | Dofetilide
| KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 | 0.41270 | Ibutilide fumarate
| 0.025318 | KCNK2: potassium channel, subfamily K, member 2 |
| 958 | N | N | N | Bupivacaine hydrochloride
| KCNC1: potassium voltage-gated channel, Shaw-related subfamily, member 1 | 0.34146 | Flecainide acetate
| 0.22153 | KCND3: potassium voltage-gated channel, Shal-related subfamily, member 3 |
| 963 | N | N | N | Halazepam
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.41667 | Bendroflumethiazide
| 0.011447 | GABRA1: gamma-aminobutyric acid (GABA) A receptor, alpha 1 |
| 964 | N | N | N | Amiloride hydrochloride
| SCN3A: sodium channel, voltage-gated, type III, alpha subunit | 0.36000 | Lamotrigine
| 0.12915 | CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit |
| 965 | N | N | N | Tolbutamide
| SCN10A: sodium channel, voltage-gated, type X, alpha subunit | 0.45833 | Lidocaine
| 0.010834 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 967 | N | N | N | Dibucaine
| KCNH2: potassium voltage-gated channel, subfamily H (eag-related), member 2 | 0.40476 | Halofantrine hydrochloride
| 0.0091581 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 971 | N | N | N | Galantamine hydrobromide
 | KCNB2: potassium voltage-gated channel, Shab-related subfamily, member 2 | 0.36111 | Quinine hydrochloride hydrate
| 0.015233 | CHRNA3: cholinergic receptor, nicotinic, alpha 3 |
| 973 | N | N | N | Glyclopyramide
| KCNMA1: potassium large conductance calcium-activated channel, subfamily M, alpha member 1 | 0.32000 | Diazoxide
| 0.0097843 | KCNJ11: potassium inwardly-rectifying channel, subfamily J, member 11 |
| 976 | N | N | N | Verapamil
| GRIN3B: glutamate receptor, ionotropic, N-methyl-D-aspartate 3B | 0.28261 | Haloperidol
| 0.026014 | KCNE1: potassium voltage-gated channel, Isk-related family, member 1 |
| 977 | N | N | N | Zonisamide
| GRIN3A: glutamate receptor, ionotropic, N-methyl-D-aspartate 3A | 0.29167 | Felbamate
| 0.022827 | SCN4B |
| 978 | N | N | N | Carbamazepine
| CACNA1G: calcium channel, voltage-dependent, T type, alpha 1G subunit | 0.37037 | Phenytoin
| 0.13386 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |
| 981 | N | N | N | Caffeine
| KCNK12: potassium channel, subfamily K, member 12 | 0 | Halothane
| 0.019268 | P2RX6: purinergic receptor P2X, ligand-gated ion channel, 6 |
| 986 | N | N | N | Gallopamil hydrochloride
 | CHRNA2 | 0.36508 | Metocurine iodide
 | 0.010362 | CACNA1S: calcium channel, voltage-dependent, L type, alpha 1S subunit |
| 988 | N | N | N | Nateglinide
| HTR3A: 5-hydroxytryptamine (serotonin) receptor 3A | 0.48387 | Granisetron
| 0.017658 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 |
| 990 | N | N | N | Amiloride hydrochloride
| SCN4A: sodium channel, voltage-gated, type IV, alpha subunit | 0.36000 | Lamotrigine
| 0.11479 | CACNA1H: calcium channel, voltage-dependent, T type, alpha 1H subunit |
| 992 | N | N | N | Biperiden
 | SLC6A2: solute carrier family 6 (neurotransmitter transporter, noradrenalin), member 2 | 0.36364 | Cocaine
| 0.020712 | CHRNA2 |
| 996 | N | N | N | Kainic acid hydrate
| CLCN2: chloride channel 2 | 0.22857 | Lubiprostone
| 0.012355 | GRIK4: glutamate receptor, ionotropic, kainate 4 |
| 997 | N | N | N | Prilocaine
 | KCNJ1: potassium inwardly-rectifying channel, subfamily J, member 1 | 0.47826 | Tolbutamide
| 0.0099976 | SCN5A: sodium channel, voltage-gated, type V, alpha subunit |